STOCK TITAN

Xtant Medical to Issue Third Quarter 2020 Financial Results on October 29, 2020

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BELGRADE, Mont., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2020, before the open of the financial markets on Thursday, October 29, 2020.

Sean Browne, President and Chief Executive Officer, and Greg Jensen, Vice President, Finance and Chief Financial Officer, will host a conference call on Thursday, October 29 at 9:00 AM ET to review results.

Conference Call Details
Date: Thursday, October 29, 2020 – 9:00 AM ET
Dial-in: 877-407-6184
International dial-in: 201-389-0877
Conference Call Name: Xtant Medical Third Quarter 2020 Financial Results
Webcast Registration: Click Here

Following the live call, a replay will be available on the Company’s website, www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

Investor Relations Contact

David Carey
Lazar FINN Partners
Ph: 212-867-1768
Email: david.carey@finnpartners.com

 

Xtant Medical Holdings, Inc.

NYSE:XTNT

XTNT Rankings

XTNT Latest News

XTNT Stock Data

104.17M
39.72M
8.16%
69.27%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BELGRADE

About XTNT

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.